MARKET

LIFE

LIFE

Atyr Pharma Inc
NASDAQ
2.470
+0.020
+0.82%
After Hours: 2.490 +0.02 +0.81% 17:04 02/07 EST
OPEN
2.480
PREV CLOSE
2.450
HIGH
2.550
LOW
2.430
VOLUME
211.48K
TURNOVER
0
52 WEEK HIGH
6.62
52 WEEK LOW
2.000
MARKET CAP
71.65M
P/E (TTM)
-1.4984
1D
5D
1M
3M
1Y
5Y
Analysts Have Conflicting Sentiments on These Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and aTyr Pharma (LIFE)
TipRanks · 17h ago
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
Benzinga · 17h ago
aTyr gains as late-stage study for lead asset brings $10M payment
Seeking Alpha · 1d ago
aTyr Pharma's Partner Kyorin Pharmaceutical Co Has Dosed The First Patient In Japan In The EFZO-FIT Phase 3 Study Evaluating Efficacy & Safety Of aTyr's Lead Candidate, Efzofitimod, For Pulmonary Sarcoidosis, A Major Form Of Interstitial Lung Disease
Benzinga · 1d ago
aTyr Pharma to Obtain $10 Million in Milestone Payment After Partner Starts Dosing Patients in Lung Disease Study in Japan
aTyr Pharma to Obtain $10 Million in Milestone Payment After Partner Starts Dosing Patients in Lung Disease Study in Japan
MT Newswires · 1d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 4d ago
BRIEF-aTyr Pharma To Present New Data On Mechanism Of Action Of Efzofitimod At American Thoracic Society 2023 International Conference
Reuters · 01/31 13:45
BRIEF-Atyr Pharma Gains E.U. Patent Covering Use Of Efzofitimod With Pirfenidone For Lung Inflammation Or Fibrosis
Reuters · 01/19 13:07
More
About LIFE
aTyr Pharma, Inc. is a biotherapeutics company engaged in the discovery and development of medicines based on novel biological pathways. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The Company is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.

Webull offers kinds of aTyr Pharma Inc stock information, including NASDAQ:LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LIFE stock methods without spending real money on the virtual paper trading platform.